



PRESS RELEASE



Embargo: March 15, 2006 at 8:30 AM (Brussels time)

SOLVAY PHARMACEUTICALS SIGNS ADDITIONAL AGREEMENT TO GET MAXIMUM GLOBAL EXPANSION FOR ANDROGEL®

Leading male hormone treatment now comes to market on five continents

Solvay Pharmaceuticals today announces the signing of additional agreements for important geographical expansions to one of its top selling products AndroGel® with the pharmaceutical company Besins International. AndroGel® is market leader in the segment of Testosterone Replacement Therapy (TRT) and one of Solvay's solid performers; in 2005 Solvay sales exceeded EUR 235 million Euro in the USA, Canada and Germany.

Solvay Pharmaceuticals now acquires exclusive distribution rights for Latin America (including Brazil and Argentina), for several countries in Asia and for all African countries. Semi-exclusive rights are now acquired for five additional European countries (France, Belgium, UK, Spain, Greece).

“Solvay is very pleased with this second major geographical expansion for AndroGel®, which is in line with the Group's policy to globalize our marketing efforts for key products”, said Sjirk Kok, Senior Vice President Global Product Strategy for Solvay Pharmaceuticals. “There is a real clinical unmet need for an easy to apply treatment for testosterone deficiency or hypogonadism, a troublesome male condition, and the profile of AndroGel® is matching that need perfectly”, he added.

AndroGel® is a once-daily, odorless, topical 1% testosterone gel used to treat men with deficiency or absence of testosterone (called hypogonadism). Symptoms of Low testosterone levels include low sex drive, reduced lean body mass, decreased bone mineral density, depressed mood and fatigue.

SOLVAY PHARMACEUTICALS (www.solvaypharmaceuticals.com) is a research driven group of pharmaceutical companies that constitute the global pharmaceutical business of the Solvay Group. Seeking to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, pancreatic enzymes, gastroenterology and men's and women's health. Solvay Pharmaceuticals employs about 13,000 people worldwide after the acquisition of Fournier Pharma in 2005.

SOLVAY is an international chemicals and pharmaceuticals group with headquarters in Brussels. It is present in more than 50 countries and employs some 30,000 people in its Chemicals, Plastics and Pharmaceuticals activities. Including Fournier Pharma, its 2005 sales amounted to EUR 8.6 billion. Solvay is listed on the Euronext 100 index of top European companies. Details are available at www.solvay.com.

For further information please contact ;

SOLVAY S.A. Headquarters

Martial Tardy

Corporate Press Officer

Telephone : 32/2/509.72.30

E-mail : martial.tardy@solvay.com

Internet : www.solvaypress.com

SOLVAY PHARMACEUTICALS

Robert van Bijlert

Pharmaceuticals Communications

Telephone: +31 (0) 294 479 577

Fax: +31 (0) 294 477 112

E-mail: robert.vanbijlert@solvay.com

Ce communiqué de presse est également disponible en français – Dit persbericht is ook in het Nederlands beschikbaar